All Sauce from Weekly Sauce:

The injectable weight-loss drug Zepbound appears to work better in women than in men, according to a new analysis of the clinical trials that led to its approval. All doses of tirzepatide consistently reduced weight in both women and men, researchers found. But women lost up to 25% of their initial body weight when treated…  read on >  read on >

Two monoclonal antibody treatments to slow Alzheimer’s disease, lecanemab (Leqembi) and donanemab (Kisunla), have been approved by the U.S. Food and Drug Administration over the past two years. It’s thought the drugs curb Alzheimer’s by reducing levels of toxic amyloid protein plaques in the brain. But what if another neurological effect could explain the benefit?…  read on >  read on >

Ozempic and Wegovy can prevent heart problems in overweight and obese people, particularly if they also suffer from kidney disease, a new clinical trial shows. The drugs’ active ingredient, semaglutide, reduced heart health risk by 20% in heavyset people who took it for more than three years, researchers reported Wednesday at the European Association for…  read on >  read on >

Less than half of people who’ve survived a stroke will go on to have a healthy, normal sleep pattern, new research shows. Normal sleep is defined as six to eight hours of shuteye nightly. However, a majority of the nearly 1,600 stroke survivors in the new study got either too much or too little sleep.…  read on >  read on >

The U.S. Food and Drug Administration announced Tuesday that it will launch an independent review into any possible effects of toxic metals found in tampons. The announcement follows the release of a study in July that found traces of lead and other metals in 30 tampons from 14 brands obtained from major online retailers and…  read on >  read on >

The weight-loss drug liraglutide helped obese children lower their BMI and reach a healthier weight, researchers report. The findings, published Tuesday in the New England Journal of Medicine and presented simultaneously at the European Association for the Study of Diabetes annual meeting in Madrid, are the first to demonstrate the effects of liraglutide (Saxenda) on children…  read on >  read on >